Published by linker 5
Posted on February 25, 2021
4 min readLast updated: January 21, 2026
According to a new market study by Future Market Insights (FMI), the global therapeutic nuclear medicines market will expand at a healthy rate between 2018 and 2028. The growth of the market is majorly attributed to factors such as the growing acceptance rate of therapeutic nuclear medicines, also known as radiopharmaceuticals, among consumers and medical professionals. These medicines have proven to be largely free of negative side-effects and minimal risk factors.
Furthermore, the rising prevalence of prostate cancer is acting as a major growth attribute to the market. As the per statistics of the U.K. cancer research organization, prostate cancer is the most prevalent cancer among men with over 47,151 cases being diagnosed in 2015. Likewise, the American Cancer Society states that prostate cancer is the most common cause of death in the US.
As the demand for safer, reliable, and less harmful drugs continues to increase in cancer treatment, therapeutic nuclear medicines are finding significant adoption among cancer patients. Along similar lines, continually increasing incidence of bone metastases is also bolstering the growth of the market.
“Owing to the stringent regulations by the US Food and Drugs Administration (FDA), market players are working on complying with the guidelines to receive approvals”, opines FMI analyst.
For more insights into the Market, Request a Sample of this Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-2930
Therapeutic Nuclear Medicines Market – Key Takeaways
Therapeutic Nuclear Medicines Market – Key Trends
For any Queries Linked with the Report, Ask an Analyst@ https://www.futuremarketinsights.com/ask-the-analyst/rep-gb-2930
Therapeutic Nuclear Medicines Market – Regional Analysis
Therapeutic Nuclear Medicines Market – Competitive Landscape
Key players operating in the market include some of the key players profiled in the therapeutic nuclear medicines market report include Bayer AG, Novartis AG, GE Healthcare, Curium Pharmaceuticals, Jubilant DraxImage, Spectrum Pharmaceuticals, Progenics Pharmaceuticals, Inc., ANSTO, Lantheus Medical Imaging, Inc., Eckert & Ziegler and International Isotopes Inc. The competitive landscape represents a highly consolidated structure with the top three players – GE Healthcare, Novartis AG, and Bayer accounting for nearly 87% of market share.
For information on the Research Approach used in the Report, Request Methodology@ https://www.futuremarketinsights.com/askus/rep-gb-2930
Therapeutic Nuclear Medicines Market – Taxonomy
Treatment type:
Indication:
Distribution channel:
Explore more articles in the Research Reports category
